How long should apixaban be withheld before a percutaneous nephrostomy?

Apixaban Withholding Before Percutaneous Nephrostomy

Withhold apixaban for at least 48 hours prior to percutaneous nephrostomy, as this procedure carries moderate-to-high bleeding risk due to the potential for significant hemorrhage and difficulty achieving immediate surgical hemostasis.

Bleeding Risk Classification

Percutaneous nephrostomy is classified as a moderate-to-high bleeding risk procedure because:

• It involves deep tissue puncture with potential for vascular injury 1
• Surgical hemostasis cannot be easily or immediately controlled 1
• Retroperitoneal bleeding can be life-threatening and difficult to detect early

Standard Interruption Protocol

For Normal Renal Function (CrCl ≥30 mL/min)

Discontinue apixaban at least 48 hours before the procedure 2. This represents the FDA-approved minimum interruption interval for procedures with moderate or high bleeding risk 2.

• The last dose should be taken 3 days before the procedure (with day 0 being the procedure day) 1
• This provides approximately 72 hours of drug-free time, ensuring minimal residual anticoagulant effect 1

For Impaired Renal Function

Extend the interruption period based on creatinine clearance:

• CrCl 30-50 mL/min: Withhold for at least 72-96 hours (3-4 days) before the procedure 3, 1
• CrCl <30 mL/min: Consider extending interruption up to 5 days, though apixaban is generally not recommended at these levels 1

The longer interruption is necessary because apixaban clearance is significantly reduced with declining renal function 3.

Additional Risk Factors Requiring Extended Interruption

Consider extending the interruption period to 4-5 days if the patient has:

• Age ≥80 years 1
• Concomitant use of P-glycoprotein inhibitors 1
• Concomitant use of CYP3A4 inhibitors 3, 1
• Severely impaired hepatic function 3

These factors can increase apixaban plasma concentrations and prolong its anticoagulant effect 3, 1.

Bridging Anticoagulation

Bridging with heparin is NOT generally required during the 48-hour interruption period 2. The evidence from the PAUSE trial demonstrated that standardized DOAC interruption without bridging resulted in very low rates of arterial thromboembolism (0.16% for apixaban) 3.

Bridging should only be considered in patients at very high thrombotic risk, which requires individualized multidisciplinary assessment 1.

Verification of Adequate Interruption

In most cases, following the time-based interruption protocol is sufficient 1. However, if the procedure must be performed urgently or there is concern about drug accumulation:

• Measure apixaban-calibrated anti-factor Xa levels 3
• Target level: ≤30 ng/mL is considered clinically insignificant anticoagulation 4
• A study of 111 patients showed that 94% achieved levels ≤30 ng/mL after appropriate interruption 4

Resumption After Procedure

Resume apixaban only after adequate hemostasis is established 2:

• Typically restart 48-72 hours post-procedure for high bleeding risk interventions 1
• If venous thromboprophylaxis is needed immediately, use heparin (UFH or LMWH) starting at least 6 hours after the procedure 1
• Avoid overlapping heparin and apixaban 1

Critical Pitfalls to Avoid

• Do not use the 24-hour interruption protocol: This is only appropriate for low bleeding risk procedures where bleeding would be non-critical and easily controlled 2, which does not apply to nephrostomy
• Do not rely on standard coagulation tests (INR, aPTT): These are insensitive for detecting residual apixaban effect 3
• Do not forget to assess renal function: Recent creatinine clearance calculation is essential for determining appropriate interruption duration 1
• Do not automatically bridge: The PAUSE trial evidence supports omitting bridging in most patients 3